Microsatellite instability in thyroid tumours and tumour-like lesions

被引:27
作者
Lazzereschi, D
Palmirotta, R
Ranieri, A
Ottini, L
Veri, MC
Cama, A
Cetta, F
Nardi, F
Colletta, G
Mariani-Costantini, R
机构
[1] Univ G DAnnunzio, Dept Oncol & Neurosci, Lab Gen Pathol, I-66100 Chieti, Italy
[2] Univ Rome La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy
[3] Univ Siena, Nuovo Policlin, Inst Surg Clin, I-53100 Siena, Italy
关键词
thyroid tumour; microsatellite instability; RER+ phenotype; lymph node metastasis; transforming growth factor beta type II receptor gene; insulin-like growth factor II receptor gene;
D O I
10.1038/sj.bjc.6690054
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fifty-one thyroid tumours and tumour-like lesions were analysed for instability at ten dinucleotide microsatellite loci and at two coding mononucleotide repeats within the transforming growth factor β (TGF-β) type II receptor (TβRII) and insulin-like growth factor II (IGF-II) receptor (IGFIIR) genes respectively. Microsatellite instability (MI) was detected in 11 out of 51 cases (21.5%), including six (11.7%) with MI at one or two loci and five (9.8%) with MI at three or more loci (RER+ phenotype). No mutations in the TβRII and IGFIIR repeats were observed. The overall frequency of MI did not significantly vary in relation to age, gender, benign versus malignant status and tumour size. However, widespread MI was significantly more frequent in follicular adenomas and carcinomas than in papillary and Hurthle cell tumours: three out of nine tumours of follicular type (33.3%) resulted in replication error positive (RER+), versus 1 out of 29 papillary carcinomas (3.4%, P = 0.01), and zero out of eight Hurthle cell neoplasms. Regional lymph node metastases were present in five MI-negative primary cancers and resulted in MI-positive in two cases.
引用
收藏
页码:340 / 345
页数:6
相关论文
共 42 条
[1]  
Blaydes JP, 1996, INT J CANCER, V65, P525, DOI 10.1002/(SICI)1097-0215(19960208)65:4<525::AID-IJC22>3.0.CO
[2]  
2-7
[3]  
BONGARZONE I, 1989, ONCOGENE, V4, P1457
[4]  
BOYER JC, 1995, CANCER RES, V55, P6063
[5]  
Brattain Michael G., 1996, Current Opinion in Oncology, V8, P49, DOI 10.1097/00001622-199601000-00009
[6]  
CIVITELLI S, 1996, INT J COLORECTAL DIS, V11, P571
[7]  
COLLETTA G, 1989, CANCER RES, V49, P3457
[8]  
Coppa A, 1997, J CELL PHYSIOL, V172, P200, DOI 10.1002/(SICI)1097-4652(199708)172:2<200::AID-JCP7>3.0.CO
[9]  
2-S
[10]  
DIRENZO MF, 1992, ONCOGENE, V7, P2549